Latest Content

Filippo Pietrantonio, MD, discusses findings from the phase 1/2 OrigAMI-1 study in RAS/BRAF wild-type mCRC.

Zanidatamab shows promise in extending survival for patients with HER2-positive biliary tract cancer, marking a significant breakthrough in treatment options.

Reduced doses and shorter durations of venetoclax can enhance treatment outcomes and reduce adverse events in acute myeloid leukemia (AML).

Johnson & Johnson partners with the Trump Administration to lower drug prices and utilize TrumpRx.com, joining a growing list of pharmaceutical companies.

Patients with unresectable stage III non–small cell lung cancer (NSCLC) had previously received neoadjuvant chemoimmunotherapy.

Circulating tumor DNA shows promise in detecting esophageal cancer recurrence earlier than traditional methods, enhancing posttreatment surveillance.

Asian women with breast cancer receiving chemotherapy had the highest persistent chemotherapy-induced alopecia (PCIA) incidence and alopecia-related distress vs their White, Black, and Hispanic or Latino peers.

The maternal morbidity was compared between states that passed laws to regulate providers with states that did not.

This week, we look at 5 key health care changes the Trump Administration made in 2025, changes to the immunization schedule, and new research on telehealth accessibility.